cytidine has been researched along with Myelodysplastic Syndromes in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (75.00) | 29.6817 |
| 2010's | 1 (25.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chan, K; Covey, J; Ebrahem, Q; Engelke, KJ; Gu, X; Jankowska, A; Ling, Y; Maciejewski, J; Mahfouz, RZ; Radivoyevitch, T; Saunthararajah, Y; Sekeres, MA; Tabarroki, A; Terse, P; Tiu, R; Visconte, V | 1 |
| Leone, G; Lübbert, M; Teofili, L; Voso, MT | 1 |
| Aggerholm, A; Antunovic, P; Astermark, J; Bernell, P; Engström, LM; Grövdal, M; Hellström-Lindberg, E; Hokland, P; Jacobsen, SE; Khan, R; Kjeldsen, L; Linder, O; Nilsson, L; Oberg, G; Olsson, A; Porwit, A; Tangen, JM; Wallvik, J | 1 |
| Issa, JP; Oki, Y | 1 |
2 review(s) available for cytidine and Myelodysplastic Syndromes
| Article | Year |
|---|---|
Inhibitors of DNA methylation in the treatment of hematological malignancies and MDS.
Topics: Acetylation; Azacitidine; Cytidine; Decitabine; DNA Methylation; Hematologic Neoplasms; Histones; Humans; Leukemia, Myeloid; Myelodysplastic Syndromes | 2003 |
Review: recent clinical trials in epigenetic therapy.
Topics: Animals; Antimetabolites, Antineoplastic; Azacitidine; Clinical Trials as Topic; Cytidine; Decitabine; DNA Methylation; Epigenesis, Genetic; Genetic Therapy; Histone Deacetylases; Humans; Myelodysplastic Syndromes | 2006 |
1 trial(s) available for cytidine and Myelodysplastic Syndromes
| Article | Year |
|---|---|
Negative effect of DNA hypermethylation on the outcome of intensive chemotherapy in older patients with high-risk myelodysplastic syndromes and acute myeloid leukemia following myelodysplastic syndrome.
Topics: Age Factors; Aged; Aged, 80 and over; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Cells; Cadherins; Cyclin-Dependent Kinase Inhibitor p15; Cytidine; Daunorubicin; DNA Methylation; Female; Humans; Kruppel-Like Transcription Factors; Leukemia, Myelomonocytic, Chronic; Male; Middle Aged; Myelodysplastic Syndromes; Prospective Studies; Remission Induction; Treatment Outcome | 2007 |
1 other study(ies) available for cytidine and Myelodysplastic Syndromes
| Article | Year |
|---|---|
Increased CDA expression/activity in males contributes to decreased cytidine analog half-life and likely contributes to worse outcomes with 5-azacytidine or decitabine therapy.
Topics: Animals; Azacitidine; Cytarabine; Cytidine; Cytidine Deaminase; Decitabine; DNA (Cytosine-5-)-Methyltransferase 1; DNA (Cytosine-5-)-Methyltransferases; Female; Gene Expression Regulation, Neoplastic; Humans; Leukemia, Myeloid, Acute; Male; Mice; Myelodysplastic Syndromes; Polymorphism, Single Nucleotide; Survival Analysis; Treatment Outcome | 2013 |